

	DOMICILIO		
<b>INFORME DE ANATOMÍA (ES COPIA)</b>			
	POBLACIÓN		C.P.
SERVICIO PROCEDENCIA	Nº DE ESTUDIO	Fecha	15/07/19

**Datos Clínicos :**

**Descripción Macroscópica :**

Identificado como biopsia muscular de deltoides se recibe en formol un fragmento tisular pardo y elástico que mide 10 x 5 mm. Se realiza un corte sagital incluyéndose en su totalidad en un bloque (A1).

**Descripción Microscópica :**

Histológicamente se observa un músculo con arquitectura general conservada no identificándose aumento del tejido conectivo endomisial. No se observan fenómenos de miofagocitosis, atrofia, internalización nuclear ni necrosis. Se realizan técnicas de HLA, CD20, CD3, CD4 y CD8 siendo negativas.No se pueden realizar algunas técnicas enzimáticas (como ORO, SDH y ATPasas) debido a que la muestra viene remitida en formol.

**Diagnóstico :**

BIOPSIA MUSCULAR (DELTOIDES IZQUIERDO):MÚSCULO NO ENTERAMENTE SATISFACTORIO PARA DIAGNÓSTICO.NO SE OBSERVAN ALTERACIONES HISTOLÓGICAS RESEÑABLES.

500000541

**FIRMA:** \_\_\_\_\_

mi consulta con  
el reumatólogo

Dan L. Longo, M.D., *Editor*

## Statin-Associated Autoimmune Myopathy

Andrew L. Mammen, M.D., Ph.D.

From the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, and the Johns Hopkins University School of Medicine, Baltimore — both in Maryland. Address reprint requests to Dr. Mammen at the Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 50 South Dr., Rm. 1146, Bldg. 50, MSC-8024, Bethesda, MD 20892, or at [andrew.mammen@nih.gov](mailto:andrew.mammen@nih.gov).

*N Engl J Med* 2016;374:664-9.

DOI: 10.1056/NEJMr1515161

Copyright © 2016 Massachusetts Medical Society.

STATINS SIGNIFICANTLY REDUCE THE INCIDENCE OF CARDIOVASCULAR disease, are generally safe, and have an acceptable side-effect profile. Indeed, a recent meta-analysis confirmed that mild musculoskeletal problems, such as myalgia, occur in approximately equal numbers of persons treated with statins and those given placebo.<sup>1</sup> Only in rare cases, in approximately 1 of 10,000 treated persons per year,<sup>2</sup> do statins cause serious muscle damage, with weakness and elevated levels of creatine kinase. In the majority of such cases, the patients recover spontaneously after the statin treatment is discontinued.<sup>3,4</sup> It is now recognized, however, that in very rare cases, an autoimmune myopathy develops in patients treated with statins; this disorder is characterized by muscle weakness, evidence of muscle-cell necrosis on biopsy, and the presence of autoantibodies against 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.<sup>5-16</sup> In contrast to most patients who have side effects from statin therapy, those with statin-associated autoimmune myopathy may have progressive weakness that must be

# Case 22-2019: A 65-Year-Old Woman with Weakness, Dark Urine, and Dysphagia

Mason W. Freeman, M.D., Ajay K. Singh, M.D., Amanda C. Guidon, M.D., Sheila L. Arvikar, M.D., Robert H. Goldstein, M.D., Ph.D., and Nathan F. Clement, M.D.

**Article**   **Figures/Media**

Metrics

19 References   1 Citing Article

July 18, 2019

N Engl J Med 2019; 381:275-283

DOI: 10.1056/NEJMcpc1900589

## Presentation of Case

**D**R. DOLL L. GOLDEN (MEDICINE): A 65-YEAR-OLD WOMAN WAS ADMITTED TO THIS hospital because of falls, weakness, dark urine, and difficulty swallowing.

Approximately 35 years before the current admission, the patient underwent staged male-to-female sex reassignment surgery at another hospital, with orchiectomy, penectomy, and urethral fixation, followed by scrotoplasty and vaginal construction. Estrogen therapy was prescribed.

### Editors

Richard C. Cabot, Founder, Eric S. Rosenberg, M.D., Editor, Virginia M. Pierce, M.D., Associate Editor, David M. Dudzinski, M.D., Associate Editor, Meridale V. Baggett, M.D., Associate Editor, Dennis C. Sgroi, M.D., Associate Editor, Jo-Anne O. Shepard, M.D., Associate Editor, Kathy M. Tran, M.D., Case Records Editorial Fellow, Emily K. McDonald, Production Editor, Sally H. Ebeling, Production Editor





**Sacyl**

Sanidad de Castilla y León

# ANALISIS CLINICOS

Apellidos :

Nombre :

Historia :

Sexo : **Hombre**

Nº Petición :

Servicio Peticionario : **CONSULTA EXTERNA**

Cama - Habitación :

OBSERVACIONES: **HMG CoA reductasa**

Destino : **MEDICINA INTERNA 1**

Servicio/C.Salud: **NO INFORMADO**

Dr./Dra :

Fecha solicitud

**PRUEBA**

**RESULTADO**

**UNIDADES**

**VALOR REFERENCIA**

## LABORATORIO EXTERNO


GENERICO


VALORACIÓN DE ANTICUERPOS ANTI HMGCR (HMG COA REDUCTASA) EN SUERO POR ENZIMOINMUNOANÁLISIS:

Resultado: Índice 3.52

Valores de referencia indicativos:

Se considera resultado positivo cuando el índice es  $>1.00$





### Fecha

Fecha	Resultado	Val. Ref.
07/09/2018 10:40:00	1487 UI/L	[20 - 200]
10/04/2019 09:33:00	3649 UI/L	[20 - 200]
09/05/2019 12:06:00	4317 UI/L	[20 - 200]
10/09/2019 13:26:00	3701 UI/L	[20 - 200]
07/10/2019 11:24:00	1889 UI/L	[20 - 200]